metoprolol-ratiopharm retard 50 mg toimeainet prolongeeritult vabastav tablett
ratiopharm gmbh - metoprolool - toimeainet prolongeeritult vabastav tablett - 50mg 100tk; 50mg 28tk; 50mg 98tk; 50mg 10tk; 50mg 50tk; 50mg 250tk; 50mg 30tk; 50mg 60tk
simvastatin-ratiopharm õhukese polümeerikattega tablett
ratiopharm gmbh - simvastatiin - õhukese polümeerikattega tablett - 40mg 50tk
simvastatin-ratiopharm õhukese polümeerikattega tablett
ratiopharm gmbh - simvastatiin - õhukese polümeerikattega tablett - 10mg 50tk; 10mg 30tk
metformin-ratiopharm 850 mg õhukese polümeerikattega tablett
ratiopharm gmbh - metformiin - õhukese polümeerikattega tablett - 850mg 120tk
omeprazole-ratiopharm gastroresistentne kõvakapsel
ratiopharm gmbh - omeprasool - gastroresistentne kõvakapsel - 20mg 15tk; 20mg 100tk; 20mg 30tk; 20mg 60tk
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - klopidogreelvesinikkloriid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombootilised ained - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
pantoprazol - ratiopharm 20 mg gastroresistentne tablett
ratiopharm gmbh - pantoprasool - gastroresistentne tablett - 20mg 15tk; 20mg 120tk; 20mg 100tk; 20mg 28tk; 20mg 56tk; 20mg 98tk; 20mg 14tk; 20mg 50tk; 20mg 7tk
nebivolol-ratiopharm 5 mg tablett
ratiopharm gmbh - nebivolool - tablett - 5mg 60tk; 5mg 56tk; 5mg 98tk; 5mg 28tk; 5mg 10tk; 5mg 50tk; 5mg 14tk; 5mg 30tk; 5mg 84tk
olanzapin-ratiopharm tablett
ratiopharm gmbh - olansapiin - tablett - 10mg 7tk; 10mg 98tk; 10mg 35tk; 10mg 28tk; 10mg 56tk; 10mg 10tk; 10mg 30tk; 10mg 14tk
ibuprofen-ratiopharm 400 mg õhukese polümeerikattega tablett
ratiopharm gmbh - ibuprofeen - õhukese polümeerikattega tablett - 400mg 10tk; 400mg 250tk; 400mg 12tk; 400mg 60tk; 400mg 30tk; 400mg 6tk; 400mg 50tk; 400mg 20tk